United Therapeutics Corporation $UTHR Stock Holdings Boosted by Retirement Systems of Alabama

Retirement Systems of Alabama grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 0.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 118,982 shares of the biotechnology company’s stock after purchasing an additional 794 shares during the quarter. Retirement Systems of Alabama’s holdings in United Therapeutics were worth $34,189,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of UTHR. Vanguard Group Inc. grew its holdings in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after acquiring an additional 15,312 shares during the period. Assetmark Inc. boosted its position in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after purchasing an additional 197,384 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of United Therapeutics by 0.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after purchasing an additional 4,145 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec raised its holdings in shares of United Therapeutics by 22.5% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock worth $147,278,000 after purchasing an additional 87,664 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of United Therapeutics by 46.1% in the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock worth $143,381,000 after purchasing an additional 146,664 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.4%

Shares of United Therapeutics stock opened at $453.53 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $479.50. The stock has a market cap of $20.46 billion, a PE ratio of 17.19, a price-to-earnings-growth ratio of 4.96 and a beta of 0.66. The business has a fifty day simple moving average of $407.40 and a 200-day simple moving average of $336.86.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the prior year, the business earned $6.39 EPS. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 364,435 shares of company stock worth $151,067,172 over the last ninety days. 10.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on UTHR. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, July 8th. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. UBS Group upped their target price on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a report on Monday, September 29th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Wednesday. Seven analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $483.73.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.